IL17A and acquired polycythemia vera: (193) reported the treatment of a PV patient with ustekinumab, an inhibitor of the p40 subunit of IL-12 and IL-23, after one month, the patient showed significant improvement in clinical symptoms and reduced serum levels of IL-12, IL-17, IFN-γ, and IL-6 without any adverse effects.